登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Cell，5月10日，Rapid Implementation of a SARS-CoV-2 Diagnostic qRT-PCR Test with Emergency Use Authorization at a Large Academic Safety-Net Hospital》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-05-12

  • Rapid Implementation of a SARS-CoV-2 Diagnostic qRT-PCR Test with Emergency Use Authorization at a Large Academic Safety-Net Hospital

    Kim Vanuytsel, PhD 1, 2, ∗

    Aditya Mithal, BA 1, ∗

    Richard M. Giadone, BS 1, ∗

    Nancy S. Miller, MD 3

    Christopher D. Andry, MPhil, PhD 3

    George J. Murphy, PhD 1, 2

    Published:May 10, 2020DOI:https://doi.org/10.1016/j.medj.2020.05.001

    Summary

    The COVID-19 pandemic is a global public health crisis. Significant delays in the rapid development and distribution of diagnostic testing for SARS-CoV-2 infection have prevented adequate public health management of the disease, impacting the timely mapping of viral spread and the conservation of personal protective equipment. Furthermore, vulnerable populations such as those served by Boston Medical Center (BMC), the largest safety net hospital in New England, represent a high-risk group across multiple dimensions, including a higher prevalence of pre-existing conditions and substance use disorders, lower health maintenance, unstable housing, and a propensity for rapid community spread, highlighting the urgent need for expedient and reliable in-house testing. Here, we report the implementation of a SARS-CoV-2 diagnostic RT-PCR assay with rapid turnaround time enabling more informed decisions with personal and public health ramifications. This work provides a blueprint for academic centers and community hospitals lacking capital-intensive automated laboratory machinery to implement in-house testing.

  • 原文来源：https://www.cell.com/med/fulltext/S2666-6340(20)30003-9
28浏览量
原文链接
相关报告

  • 《5月10日_大型学术安全网医院通过紧急使用授权快速实施SARS-CoV-2诊断qRT-PCR测试》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-12
    • 信息名称：大型学术安全网医院通过紧急使用授权快速实施SARS-CoV-2诊断qRT-PCR测试 1.时间：2020年5月10日 2.机构或团队：波士顿大学再生医学中心和波士顿医学中心 3.事件概要： 波士顿大学再生医学中心和波士顿医学中心在Cell Press发表论文“Rapid Implementation of a SARS-CoV-2 Diagnostic qRT-PCR Test with Emergency Use Authorization at a Large Academic Safety-Net Hospital”。 新冠肺炎疫情是全球公共卫生危机。SARS-CoV-2感染诊断检测的发展和分发方面的重大延误妨碍了公共卫生管理，影响了病毒传播的实时绘图。此外，弱势群体如波士顿医疗中心（BMC），新英格兰最大的安全保障医院，迫切需要有利的和可靠的内部测试。文章报告了SARS-CoV-2诊断RT-PCR检测的实施情况，该检测具有快速周转时间，能够帮助个人和公共卫生系统做出更明智的决定。这项工作为缺乏资金密集型的自动化实验室设备的学术中心和社区医院提供了一个实施内部测试的蓝图。 4.附件： 原文链接：https://www.cell.com/med/fulltext/S2666-6340(20)30003-9
    15浏览量
    原文链接

  • 《Lancet，9月17日，Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-10-13
    • Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study Malick M Gibani, D Phil † Prof Christofer Toumazou, PhD † Mohammadreza Sohbati, PhD Rashmita Sahoo, PhD Maria Karvela, PhD Tsz-Kin Hon, PhD et al. Open AccessPublished:September 17, 2020DOI:https://doi.org/10.1016/S2666-5247(20)30121-X Summary Background Access to rapid diagnosis is key to the control and management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Laboratory RT-PCR testing is the current standard of care but usually requires a centralised laboratory and significant infrastructure. We describe our diagnostic accuracy assessment of a novel, rapid point-of-care real time RT-PCR CovidNudge test, which requires no laboratory handling or sample pre-processing. Methods Between April and May, 2020, we obtained two nasopharyngeal swab samples from individuals in three hospitals in London and Oxford (UK). Samples were collected from three groups: self-referred health-care workers with suspected COVID-19; patients attending emergency departments with suspected COVID-19; and hospital inpatient admissions with or without suspected COVID-19. For the CovidNudge test, nasopharyngeal swabs were inserted directly into a cartridge which contains all reagents and components required for RT-PCR reactions, including multiple technical replicates of seven SARS-CoV-2 gene targets (rdrp1, rdrp2, e-gene, n-gene, n1, n2 and n3) and human ribonuclease P (RNaseP) as sample adequacy control. Swab samples were tested in parallel using the CovidNudge platform, and with standard laboratory RT-PCR using swabs in viral transport medium for processing in a central laboratory. The primary analysis was to compare the sensitivity and specificity of the point-of-care CovidNudge test with laboratory-based testing.
    10浏览量
    原文链接